Literature DB >> 8523083

External beam radiotherapy: hard facts and painful realities.

N A Vick1, N A Paleologos.   

Abstract

In comparison to whole brain radiotherapy, local field radiotherapy in a consecutive series of 100 patients with malignant astrocytoma resulted in remarkably less toxicity. Survivorship is not different; the advantage is limited to the 7% long term survivors (defined as living 100% or more beyond median) since toxicity from brain radiation does not occur until a year or more after treatment.

Entities:  

Mesh:

Year:  1995        PMID: 8523083     DOI: 10.1007/bf01052665

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  11 in total

Review 1.  Therapy of adult malignant brain tumors: what have the clinical trials taught us?

Authors:  W R Shapiro
Journal:  Semin Oncol       Date:  1986-03       Impact factor: 4.929

Review 2.  The long-term side effects of radiation therapy for benign brain tumors in adults.

Authors:  O al-Mefty; J E Kersh; A Routh; R R Smith
Journal:  J Neurosurg       Date:  1990-10       Impact factor: 5.115

3.  Brain necrosis after radiotherapy for primary intracerebral tumor.

Authors:  M L Hohwieler; T C Lo; M L Silverman; S R Freidberg
Journal:  Neurosurgery       Date:  1986-01       Impact factor: 4.654

4.  Effects of treatment on long-term survivors with malignant astrocytomas.

Authors:  J P Imperato; N A Paleologos; N A Vick
Journal:  Ann Neurol       Date:  1990-12       Impact factor: 10.422

5.  Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.

Authors:  K E Wallner; J H Galicich; G Krol; E Arbit; M G Malkin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

6.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.

Authors:  W R Shapiro; S B Green; P C Burger; M S Mahaley; R G Selker; J C VanGilder; J T Robertson; J Ransohoff; J Mealey; T A Strike
Journal:  J Neurosurg       Date:  1989-07       Impact factor: 5.115

7.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.

Authors:  M D Walker; E Alexander; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; H A Norrell; G Owens; J Ransohoff; C B Wilson; E A Gehan; T A Strike
Journal:  J Neurosurg       Date:  1978-09       Impact factor: 5.115

8.  Assumptions in the radiotherapy of glioblastoma.

Authors:  F H Hochberg; A Pruitt
Journal:  Neurology       Date:  1980-09       Impact factor: 9.910

Review 9.  Radiotherapy for brain tumors.

Authors:  N J Laperriere; M Bernstein
Journal:  CA Cancer J Clin       Date:  1994 Mar-Apr       Impact factor: 508.702

10.  Cognitive functioning in long-term survivors of high-grade glioma.

Authors:  Y M Archibald; D Lunn; L A Ruttan; D R Macdonald; R F Del Maestro; H W Barr; J H Pexman; B J Fisher; L E Gaspar; J G Cairncross
Journal:  J Neurosurg       Date:  1994-02       Impact factor: 5.115

View more
  3 in total

1.  Characterization of invading glioma cells using molecular analysis of leading-edge tissue.

Authors:  Cheol-Soo Kim; Shin Jung; Tae-Young Jung; Woo-Youl Jang; Heung-Suk Sun; Hyang-Hwa Ryu
Journal:  J Korean Neurosurg Soc       Date:  2011-09-30

2.  The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors.

Authors:  Nhan L Tran; Wendy S McDonough; Patrick J Donohue; Jeffrey A Winkles; Theresa J Berens; Kristen R Ross; Dominique B Hoelzinger; Christian Beaudry; Stephen W Coons; Michael E Berens
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

3.  Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide.

Authors:  Mark R Gilbert; Terri S Armstrong
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.